Selank is a commonly searched research peptide with the same easy-to-misread regulatory status as its shelf-mate Semax: available as a medicine in one part of the world and unapproved almost everywhere else. The questions to settle before ordering are the familiar ones: what is it, what does its documentation establish, and what is the regulatory context in Canada. This is a source-based summary. It is not a guide to any use, not a claim that Selank is an authorized drug in Canada or suitable for human use, and not legal or medical advice.

Identity starts with the named compound

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), a synthetic analogue of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) extended by a Pro-Gly-Pro tail. It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. A procurement record should begin with the compound name, that identity, the selected strength, and the lot, so a receiving laboratory can reconcile what was ordered against the label and the source document. Those fields establish identity for reconciliation; they do not verify biological activity or authorize a route of use.

Regulatory status: available in one region is not approved here

Selank is available in Russian and Ukrainian pharmacies, where it is classified as a nootropic anxiolytic peptide, and it has been investigated primarily in Russian-language scientific literature. Outside that region it is a different picture: Selank is not approved by regulators in other countries and carries no FDA or EU marketing authorization. The load-bearing point for a Canadian laboratory is that availability or approval in one region does not make a material an authorized drug in Canada; an unauthorized product here has not been assessed by Health Canada for safety, efficacy, and quality, and a research-use-only label does not confer legal status — the same principle set out in our note on Canadian regulatory context for research peptides. Determining whether a given procurement, possession, import, or use complies with applicable requirements remains the purchaser’s and the receiving laboratory’s responsibility.

What a CoA can and cannot establish

A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory, and its scope is limited to the sample, methods, and results stated on that document. For Selank as for any compound, the checks are the same:

  • Match the compound, lot, and certificate identifier.
  • Read the method and the actual measured value.
  • Separate chromatographic purity from identity and potency.
  • Do not treat a CoA as regulatory approval, sterility assurance, or a substitute for an end laboratory’s validated controls unless the document expressly supports that conclusion.

Procurement boundary for Canadian laboratories

Before ordering, review the canonical product page, the posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory’s responsibility.

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. This article summarizes public regulatory and reference sources and is not legal or medical advice.